B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
IMA
ImageneBioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
IMG-007 has shown tolerability across more than 150 exposed subjects, management says ADAPTIVE is enrolling to plan, and the company now has additional financing support, so a clean 2027 readout could re-rate a stock still trading at a depressed small-cap biotech valuation [#10-K-2026-03-10].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Broad rather than near-dated catalyst calendar, with core topline only guided for 2027.
Momentum
58
Value
57
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.80Analysis 2026-04-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.00
Why
Momentum58 · Δ7d -
Value57 · Δ7d 0.0
Sentiment67 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Broad rather than near-dated catalyst calendar, with core topline only guided for 2027.
- • Early-stage safety and efficacy signals may not hold in a larger dose-ranging study.
- • IMA is still essentially a single-asset clinical story with low catalyst density before the 2027 topline, the latest material event was dilutive financing rather than efficacy data, and the deterministic prior is negative across 5d/20d/60d/120d horizons.
Catalyst clock
2026-04-14
April 2026 financing reduces near-term balance-sheet pressure but adds dilution
Lead driver: Sentiment · See AI snapshot
Momentum
58
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
67
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 58.4 / Value 57.5 / Sentiment 67.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$63.34M
Beta
0.44
Shares Out
11.35M
P/E (TTM) · Derived
-0.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.99
Rev YoY
-100.0%
EPS YoY
-85.9%
Gross Margin
+9.6%
Op Margin
-10373.9%
Net Debt
-$125.35M
Current Ratio
21.47
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data